Table 2. Number of Volunteers Enrolled, Vaccination Schedule, Sample Collection and Assessment time points.
| Groupa | Vaccines/Dosage | Preb | W0 | W2 | W4 | W24 | W25 | W26 | W28 | W32 | W38 | W52, 64 & 72 |
| A (10/4) | Ad35-GRIN/ENV 2×109 vp | c | d,e,f | d | c,d,e | d,e | d | c,d,e,f | d,e | d | d,e | d,e |
| B (10/4) | Ad35-GRIN/ENV 2×1010 vp | c | d,e,f | d | c,d,e | d,e | d | c,d,e,f | d,e | d | d,e | d,e |
| C (10/4) | Ad35-GRIN/ENV 2×1011 vp | c | d,e,f | d | c,d,e | d,e | d | c,d,e,f | d,e | d | d,e | d,e |
| D (10/4) | Ad35-GRIN 1×1010 vp | c | d,e,f | d | c,d,e | d,e | d | c,d,e,f | d,e | d | d,e | d,e |
W = week, W0 and W24 are vaccination visits.
a
(V/P) Number of Vaccine recipients/number of Placebo recipients per group.
b
Screen window up to 65 days prior to enrollment for anti-Ad35 antibodies.
c
Serum neutralizing antibodies against Ad35.
d
Vaccine-induced HIV-1 specific IFN-γ ELISPOT responses.
e
Vaccine-induced HIV-1 specific humoral immune responses (Env and p24 Gag ELISA).
f
Polychromatic Flow Cytometry.